Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 11, 2014, Pages 1576-1585

  Suico, Jeffrey G ^a   Wang, Ming Dauh ^a   Friedrich, Stuart ^a   Cannady, Ellen A ^a   Konkoy, Christopher S ^a   Ruotolo, Giacomo ^a   Krueger, Kathryn A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Cholesteryl ester transfer protein; Evacetrapib; High density lipoprotein; Pharmacodynamic; Pharmacokinetic

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN; CORTICOSTEROID; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; BENZODIAZEPINE DERIVATIVE; CETP PROTEIN, HUMAN; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG ERUPTION; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; NORMAL HUMAN; PAPULAR RASH; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT FEVER; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; DRUG EFFECTS; MIDDLE AGED; REFERENCE VALUE; YOUNG ADULT;

ADULT; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BENZODIAZEPINES; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; REFERENCE VALUES; YOUNG ADULT;

EID: 84918807616     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12287     Document Type: Article

References (21)

1. Gordon T et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-714.
2. deGoma EM et al. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol 2008; 51: 49-55.
3. Nicholls SJ. Evacetrapib. Curr Cardiol Rep 2012; 14: 245-250.
4. Cannon CP et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363: 2406-2415.
5. Barter PJ et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122.
6. Forrest MJ et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008; 154: 1465-1473.
7. Cao G et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res 2011; 52: 2169-2176.
8. Hu X et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein (CETP) inhibition. Endocrinology 2009; 150: 2211-2219.
9. Schwartz GG et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089-2099.
10. Nicholls SJ et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011; 306: 2099-2109.
11. Ferrari P. The role of 11?-hydroxysteroid dehydrogenase type 2 in human hypertension. Biochim Biophys Acta 2010; 1802: 1178-1187.
12. Smith BP et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000; 17: 1278-1283.
13. Krishna R et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther 2008; 84: 679-683.
14. Friedrich S et al. The pharmacokinetics and pharmacokinetic/pharmacodynamic relationships of evacetrapib administered as monotherapy or in combination with statins. CPT Pharmacometrics Syst Pharmacol 2014; 3: e94. doi: 10.1038/psp.2013.70.
15. Gotto AM Jr et al. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol 2014; 113: 76-83.
16. Brousseau ME et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005; 25: 1057-1064.
17. Ikewaki K et al. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest 1993; 92: 1650-1658.
18. Tall AR. The effects of cholesterol ester transfer protein inhibition on cholesterol efflux. Am J Cardiol 2009; 104(10 Suppl.): 39E-45E. doi: 10.1016/j.amjcard.2009.09.018.
19. Suico J et al. Evacetrapib at a supratherapeutic steady-state concentration does not prolong QT in a thorough QT/QTc study in healthy subjects. J Cardiovasc Pharmacol Ther 2014; 19: 283-289. doi: 10.1177/1074248413510784.
20. Johns DG et al. On-and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors. Drugs 2012; 72: 491-507.
21. Burris TP et al. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation. Mol Endocrinol 1999; 13: 410-417.